Boule Diagnostics AB will publish the interim report for the period January – September 2018 at 15:00, Tuesday, November 6. Following the publication, Boule will hold a conference call at 16:00 for media and investors.
CEO Fredrik Dalborg and CFO Christina Rubenhag presents and comment on the interim report. After the presentation there will be time for audience questions. The presentation will be held in English.
Time: 16:00 CET, Tuesday, November 6, 2018
Telephone number: +46(0) 8-744 77 22
The interim report will be accessible at http://www.boule.com when published.
Please feel free to attend this event!
For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46(0) 705-58 51 05
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46(0) 705-46 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET on November 1, 2018.